ArticleDermatologic therapy2020
Aggressive course of pemphigus vulgaris following COVID-19 infection.
Article in Dermatologic therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- COVID-19 and exacerbation of dermatological diseases: A review of the available literature.Dermatologic therapy · 2021Pooled it
- Autoimmune Skin Diseases in the Era of COVID-19: Pathophysiological Insights and Clinical Implications.Microorganisms · 2025Review
- Plasmapheresis for Facilitating Readministration of Rituximab After Paradoxical Exacerbation in Pemphigus Vulgaris: A Case Report.Clinical case reports · 2025Article
- Article
- Evaluation of link between COVID-19 adjacent spike in hydroxychloroquine use and increased reports of pemphigus: a disproportionality analysis of the FDA Adverse Event Reporting System.Frontiers in immunology · 2024Observational
- Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine.Frontiers in medicine · 2023Review
- Adverse outcome and severity of COVID-19 in patients with autoimmune bullous diseases: A historical cohort study.Dermatologic therapy · 2022Article
- Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies.Journal of clinical medicine · 2022Review
- New-onset pemphigus foliaceus following SARS-CoV-2 infection and unmasking multiple sclerosis: A case report.Clinical case reports · 2022Article
- New onset of pemphigus foliaceus following BNT162b2 vaccine.Dermatologic therapy · 2022Article
- The multifactorial complexities of autoimmune development in Pemphigus vulgaris: Critical evaluation of the role of environmental and lifestyle "exposome" factors.Frontiers in immunology · 2022Review
- Patient Quality of Life Improvement in Bullous Disease: A Review of Primary Literature and Considerations for the Clinician.Clinical, cosmetic and investigational dermatology · 2022Review
- Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab.Frontiers in immunology · 2021Article
- Case Report: Infantile Bullous Pemphigoid: Triggering by COVID-19 Is Speculative.Frontiers in medicine · 2021Article
- Impact of COVID-19 on autoimmune blistering diseases.Clinics in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.